CriteriaCaixa, the holding company that manages the business assets of ‘la Caixa’ Banking Foundation, has rebooted its start-up investment business to facilitate the growth of science and technology-based high-potential emerging companies.
Through its two funds, Criteria Bio Ventures and Criteria Venture Tech, it plans to invest €300m (US$343m) by 2030 in early-stage companies, to promote transformative therapies and technologies that can have a positive impact on society, prioritising long-term value creation. Investments will primarily be focused on Spain and Portugal, and selectively on Europe and North America – investments in Spain represent nearly 70% of the current portfolio’s value.
Caixa Capital Risc will now operate under the Criteria Capital Risc brand name.
Through its two specialised vehicles, Criteria Bio Ventures and Criteria Venture Tech, Criteria Capital Risc actively manages its investments by sitting on the boards of its portfolio companies in support of value creation. It provides strategic support, expertise, financial strength and access to leading
Criteria Bio Venturesis the investment fund of Criteria Capital Risc specialising in biotechnology and health. It aims to identify, fund and support companies developing new therapies with the potential to transform disease management and clear potential for scalability and impact.
Criteria Venture Techis Criteria Capital Risc’s investment fund specialising in technology, with a focus on deep tech and key vertical markets such as AI, cybersecurity, and software and data infrastructures. The fund invests in technology star-tups from the early stage, including pre-seed and seed, with the objective of assuming lead or co-lead positions.
